Drug intelligence / Profile preview

Rillus

Development stage: Unknown
Lead developer: Kalbe Farma
Modality: Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Inhalation Devices → Device-based Delivery → Drug Delivery Systems, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral (chewable Tablet)

Overview

Rillus is a symbiotic dietary supplement formulated as a chewable tablet containing three probiotic strains—Bifidobacterium bifidum, Streptococcus thermophilus, and Lactobacillus plantarum—combined with the prebiotic fructooligosaccharide (FOS). The product delivers 1.0 x 10^9 CFU of viable cells per tablet and is designed to promote gastrointestinal health by supporting the growth of beneficial gut bacteria. FOS serves as a growth medium for these probiotics. Rillus is primarily used to help regulate digestive function, restore normal intestinal flora, and may be recommended in cases such as diarrhea or other bowel disturbances[2][4][7].

Brand names: Rillus
Other names: Rillus synbiotic

Beyond the preview

Go deeper on Rillus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rillus.

Explore the full profile